Form 4 Sage Therapeutics, Inc. For: Apr 17 Filed by: STARR KEVIN P
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Sage Therapeutics (SAGE) Weakness is a Buying Opportunity - RBC
April 23, 2018 10:20 AM EDTRBC Capital analyst Brian Abrahams sees weakness in Sage Therapeutics (NASDAQ: SAGE) on Friday, related to insider selling and a deal with Biogen for IONS, as a buying opportunity.
"... we view these as non-fundamental, and Friday's detailed, in-line brexanolone data, today's on-track NDA filing,... More
